8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 29, 2026·SEC
Citius Pharmaceuticals, Inc.(CTXR)Earnings, Financials & Key Ratios
CTXR•NASDAQ
Price updated Jun 19, 2026
AboutCitius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.Show more
- Revenue$0
- EBITDA-$38M+8.3%
- Net Income-$37M+4.4%
- EPS (Diluted)-3.38+43.4%
- ROE-49.38%-4.4%
CTXR Key Insights
Citius Pharmaceuticals, Inc. (CTXR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 4.5% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Profits declining 16.4% over 5 years
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CTXR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CTXR Price & Volume
Citius Pharmaceuticals, Inc. (CTXR) stock price & volume — 10-year historical chart
Loading chart...
CTXR Growth Metrics
Citius Pharmaceuticals, Inc. (CTXR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM3498.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-9.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM55.99%
Return on Capital
10 Years-49.62%
5 Years-36.38%
3 Years-42.87%
Last Year-46.18%
CTXR Recent Earnings
Citius Pharmaceuticals, Inc. (CTXR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.95-344.5%
$0.39
Rev
$2M-91.1%
$19M
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.38-188.4%
$0.43
Rev
$4M-78.1%
$18M
Q4 2025
Dec 25, 2025Metric
Actual
Est
EPS
$0.44-83.5%
$0.24
Rev
$4M
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.80-233.3%
$0.24
Rev
—
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.95vs $0.39-344.5% | $2Mvs $19M-91.1% |
| Q1 2026 | Feb 13, 2026 | $0.38vs $0.43-188.4% | $4Mvs $18M-78.1% |
| Q4 2025 | Dec 25, 2025 | $0.44vs $0.24-83.5% | $4M |
| Q3 2025 | Aug 12, 2025 | $0.80vs $0.24-233.3% | —vs $2M |
Based on last 12 quarters of dataView full earnings history →
CTXR Peer Comparison
Citius Pharmaceuticals, Inc. (CTXR) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 ETON | 889.7M | 32.48 | -191.06 | 104.94% | -1.7% | -5.68% | 1.19 | |
 TLRY | 551.15M | 4.73 | -0.14 | 4.84% | -252.55% | -136.55% | 0.22 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 ACRS | 542.68M | 4.50 | -8.49 | -58.19% | -8.33% | -55.89% | 0.02 |
Compare CTXR vs Peers
Citius Pharmaceuticals, Inc. (CTXR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CTXR Income Statement
Citius Pharmaceuticals, Inc. (CTXR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.61M |
Revenue Growth % | - | - | - | - | - | - | - | - | - | 3498.76% |
Cost of Goods Sold | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K | 3.52M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -2.63K▲ 0% | -1.75K▲ 33.4% | -893▲ 49.1% | -152.36K▼ 16962.0% | -164.87K▼ 8.2% | -179.68K▼ 9.0% | -194.32K▼ 8.1% | -209.61K▼ 7.9% | -214.25K▼ 2.2% | 2.1M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | 37.36% |
Gross Profit Growth % | -95.98% | 33.4% | 49.06% | -16962.04% | -8.21% | -8.98% | -8.15% | -7.87% | -2.21% | - |
Operating Expenses | 9.99M | 13.79M | 15.6M | 17.71M | 23.53M | 33.32M | 36.73M | 42M | 38.31M | 60.54M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 7.05M | 7.23M | 7M | 8.9M | 11.29M | 15.66M | 21.91M | 18.25M | 18.53M | 40.46M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 2.94M | 6.56M | 8.6M | 8.81M | 12.24M | 17.66M | 14.82M | 11.91M | 9.16M | 6.5M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.84M | 10.62M | 2.96M |
Operating Income | -9.99M▲ 0% | -13.79M▼ 38.1% | -15.6M▼ 13.1% | -17.71M▼ 13.5% | -23.53M▼ 32.9% | -33.32M▼ 41.6% | -36.73M▼ 10.3% | -42M▼ 14.3% | -38.53M▲ 8.3% | -58.44M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | -1041.44% |
Operating Income Growth % | -34.06% | -38.08% | -13.12% | -13.54% | -32.87% | -41.58% | -10.25% | -14.33% | 8.26% | - |
EBITDA | -9.98M | -13.79M | -15.6M | -17.56M | -23.37M | -33.14M | -36.54M | -41.79M | -38.31M | -56M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | -997.99% |
EBITDA Growth % | -34.05% | -38.1% | -13.13% | -12.57% | -33.08% | -41.81% | -10.26% | -14.36% | 8.32% | -30.94% |
D&A (Non-Cash Add-back) | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K | 2.44M |
EBIT | -9.99M | -12.52M | -15.55M | -17.53M | -23.04M | -33.06M | -31.97M | -38.85M | -38.42M | -58.37M |
Net Interest Income | -849.98K | 0 | 36.22K | 52.39K | 250.99K | 0 | 1.18M | 758K | -157.7K | -283.61K |
Interest Income | 806 | 0 | 52.66K | 68.07K | 261.82K | 251.4K | 1.18M | 758K | 110.08K | 172.74K |
Interest Expense | 850.79K | 15.84K | 16.44K | 15.67K | 10.84K | 251.4K | 0 | 0 | 267.78K | 456.35K |
Other Income/Expense | -398.64K | 1.25M | 36.22K | 162.6K | 477.46K | 251.4K | 4.77M | 3.15M | -157.7K | 3.55M |
Pretax Income | -10.38M▲ 0% | -12.54M▼ 20.7% | -15.56M▼ 24.1% | -17.55M▼ 12.8% | -23.05M▼ 31.4% | -33.06M▼ 43.4% | -31.97M▲ 3.3% | -38.85M▼ 21.5% | -38.68M▲ 0.4% | -54.89M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | -978.18% |
Income Tax | 0 | 0 | 16.44K | 0 | 0 | 576K | 576K | 576K | 1.06M | 561.51K |
Effective Tax Rate % | 0% | 0% | -0.11% | 0% | 0% | -1.74% | -1.8% | -1.48% | -2.73% | -1.02% |
Net Income | -10.38M▲ 0% | -12.54M▼ 20.7% | -15.58M▼ 24.3% | -17.55M▼ 12.6% | -23.13M▼ 31.8% | -33.64M▼ 45.5% | -32.54M▲ 3.3% | -39.14M▼ 20.3% | -37.43M▲ 4.4% | -46.2M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | -823.34% |
Net Income Growth % | -25.18% | -20.72% | -24.26% | -12.64% | -31.78% | -45.47% | 3.26% | -20.27% | 4.36% | -9.88% |
Net Income (Continuing) | -10.38M | -12.54M | -15.56M | -17.55M | -23.05M | -33.64M | -32.54M | -39.43M | -39.74M | -55.45M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 600.38K | 600.38K | 600.38K | 4.02M | 9.98M | 7.54M |
EPS (Diluted) | -1.89▲ 0% | -1.17▲ 38.1% | -0.77▲ 34.2% | -0.45▲ 41.6% | -5.64▼ 1153.3% | -5.76▼ 2.1% | -5.57▲ 3.3% | -5.97▼ 7.2% | -3.38▲ 43.4% | -2.06▲ 0% |
EPS Growth % | 17.47% | 38.1% | 34.19% | 41.56% | -1153.33% | -2.13% | 3.3% | -7.18% | 43.38% | 55.99% |
EPS (Basic) | -1.89 | -1.17 | -0.77 | -0.45 | -5.64 | -5.76 | -5.57 | -5.97 | -3.38 | - |
Diluted Shares Outstanding | 365.5K | 715.46K | 1.34M | 2.61M | 7.24M | 9.74M | 10.09M | 11.59M | 11.07M | 22.38M |
Basic Shares Outstanding | 365.5K | 715.46K | 1.34M | 2.61M | 7.24M | 9.74M | 9.74M | 11.59M | 11.07M | 22.38M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CTXR Balance Sheet
Citius Pharmaceuticals, Inc. (CTXR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.42M | 10.06M | 7.94M | 13.98M | 72.81M | 44.56M | 34.37M | 14.22M | 27.93M | 31.69M |
Cash & Short-Term Investments | 3.2M | 9.18M | 7.89M | 13.86M | 70.07M | 41.71M | 26.48M | 3.25M | 4.25M | 4.59M |
Cash Only | 3.2M | 9.18M | 7.89M | 13.86M | 70.07M | 41.71M | 26.48M | 3.25M | 4.25M | 4.59M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 818.34K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.08M |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 83.39 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.27M | 22.29M | 22.66M |
Days Inventory Outstanding | - | - | - | - | - | - | - | 14.4K | 37.97K | 2.2K |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Non-Current Assets | 20.99M | 20.99M | 21.04M | 29.79M | 69.61M | 69.44M | 69.24M | 102.43M | 103M | 100.85M |
Property, Plant & Equipment | 3.24K | 1.48K | 590 | 987.78K | 829.85K | 650.17K | 455.86K | 246.25K | 818.69K | 794.52K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 6.74x |
Goodwill | 1.59M | 1.59M | 1.59M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M | 9.35M |
Intangible Assets | 19.4M | 19.4M | 19.4M | 19.4M | 59.4M | 59.4M | 59.4M | 92.8M | 92.8M | 90.51M |
Long-Term Investments | 0 | 0 | 0 | 16.92M | 29.18M | 0 | 44.91M | 0 | 0 | 0 |
Other Non-Current Assets | 2.17K | 2.17K | 57.09K | 57.09K | 38.06K | 39.97M | -44.88M | 38.06K | 38.06K | 207.31K |
Total Assets | 24.42M▲ 0% | 31.05M▲ 27.2% | 28.99M▼ 6.6% | 43.77M▲ 51.0% | 142.43M▲ 225.4% | 114M▼ 20.0% | 103.61M▼ 9.1% | 116.65M▲ 12.6% | 130.94M▲ 12.2% | 132.54M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.04x |
Asset Growth % | 11.24% | 27.17% | -6.65% | 51.01% | 225.38% | -19.96% | -9.11% | 12.59% | 12.25% | 69.16% |
Total Current Liabilities | 2.47M | 3.18M | 4.61M | 4.1M | 3.98M | 4.53M | 5.78M | 35.81M | 44.91M | 55.02M |
Accounts Payable | 602.43K | 1.57M | 2.71M | 1.86M | 1.28M | 1.17M | 2.93M | 4.93M | 13.69M | 9.45M |
Days Payables Outstanding | 83.54K | 327.61K | 1000K | 4.45K | 2.83K | 2.37K | 5.5K | 8.58K | 23.33K | 1.15K |
Short-Term Debt | 172.97K | 172.97K | 172.97K | 172.97K | 177.24K | 196.99K | 218.38K | 241.55K | 1M | 171.5K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 320.52K | 1.65M | 1.73M | 1.57M | -218.38K | -241.55K | 3.29M | 45.39M |
Current Ratio | 1.39x | 3.16x | 1.72x | 3.41x | 18.28x | 9.84x | 5.95x | 0.40x | 0.62x | 0.58x |
Quick Ratio | 1.39x | 3.16x | 1.72x | 3.41x | 18.28x | 9.84x | 5.95x | 0.17x | 0.13x | 0.16x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 1.14K |
Total Non-Current Liabilities | 0 | 1.75M | 4.99M | 6.01M | 5.66M | 6.04M | 6.4M | 6.74M | 8.5M | 8.44M |
Long-Term Debt | 0 | 0 | 0 | 164.58K | 0 | 0 | 0 | 0 | 0 | 636.67K |
Capital Lease Obligations | 0 | 0 | 0 | 855.47K | 678.23K | 481.25K | 262.87K | 21.32K | 724.92K | 2.17M |
Deferred Tax Liabilities | 0 | 0 | 4.99M | 4.99M | 4.99M | 5.56M | 6.14M | 6.71M | 7.77M | 31.12M |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.47M | 3.18M | 4.61M | 10.1M | 9.65M | 10.57M | 12.18M | 42.55M | 53.41M | 63.46M |
Total Debt | 172.97K | 172.97K | 172.97K | 1.35M | 855.47K | 678.23K | 481.25K | 262.87K | 1.81M | 808.16K |
Net Debt | -3.03M | -9.01M | -7.72M | -12.51M | -69.22M | -41.03M | -26M | -2.99M | -2.44M | -3.78M |
Debt / Equity | 0.01x | 0.01x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.07x |
Interest Coverage | -11.74x | -790.55x | -945.43x | -1118.64x | -2125.99x | -131.52x | - | - | -143.46x | -127.90x |
Total Equity | 21.95M▲ 0% | 27.87M▲ 27.0% | 24.38M▼ 12.5% | 33.67M▲ 38.1% | 132.78M▲ 294.4% | 103.43M▼ 22.1% | 91.43M▼ 11.6% | 74.1M▼ 19.0% | 77.53M▲ 4.6% | 69.08M▲ 0% |
Equity Growth % | 30.9% | 26.97% | -12.51% | 38.12% | 294.36% | -22.11% | -11.6% | -18.95% | 4.62% | 27.21% |
Book Value per Share | 60.05 | 38.95 | 18.14 | 12.90 | 18.34 | 10.62 | 9.06 | 6.39 | 7.01 | 3.09 |
Total Shareholders' Equity | 21.95M | 27.87M | 24.38M | 33.67M | 132.18M | 102.83M | 90.83M | 70.08M | 67.55M | 61.54M |
Common Stock | 8.35K | 16.2K | 28.93K | 55.58K | 145.98K | 146.21K | 158.86K | 7.25K | 18.07K | 22.38K |
Retained Earnings | -27.72M | -40.26M | -55.82M | -70.59M | -96.05M | -129.69M | -162.23M | -201.37M | -238.8M | -268.26M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 600.38K | 600.38K | 600.38K | 4.02M | 9.98M | 7.54M |
CTXR Cash Flow Statement
Citius Pharmaceuticals, Inc. (CTXR) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -7.97M | -11.32M | -12.44M | -16.93M | -24.25M | -28.36M | -29.06M | -28.2M | -26.55M | -31.6M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -35.1% | -41.99% | -9.89% | -36.12% | -43.23% | -16.95% | -2.46% | 2.96% | 5.85% | -169.46% |
Net Income | -10.38M | -12.54M | -15.56M | -17.55M | -23.05M | -33.64M | -32.54M | -39.43M | -39.74M | -46.2M |
Depreciation & Amortization | 2.63K | 1.75K | 893 | 152.36K | 164.87K | 179.68K | 194.32K | 209.61K | 214.25K | 2.42M |
Stock-Based Compensation | 986.62K | 779.7K | 715.98K | 803.26K | 1.45M | 3.91M | 6.62M | 11.84M | 10.84M | 9.89M |
Deferred Taxes | 0 | -450K | 0 | 0 | -166.56K | 576K | 576K | 576K | 1.06M | 297.27K |
Other Non-Cash Items | 1.31M | 377.2K | 211.6K | 528.77K | 68K | 378.2K | 102K | 284.18K | 26.6K | -6.47M |
Working Capital Changes | 115.52K | 509.85K | 2.2M | -866.97K | -2.72M | 239.56K | -4.01M | -1.69M | 1.05M | 9.66M |
Change in Receivables | 0 | -818.34K | 818.34K | 0 | 0 | 0 | 0 | 0 | 0 | -1.08M |
Change in Inventory | 0 | 0 | -818.34K | 0 | 0 | 0 | 0 | -2.13M | -12.65M | -5.95M |
Change in Payables | -306.73K | 971.01K | 1.14M | -857.31K | -579.14K | -111.72K | 1.76M | 2M | 8.77M | 2.76M |
Cash from Investing | -2.13K | 0 | 0 | -1.83K | -40.01M | 0 | 0 | -5M | -5.75M | -10.75M |
Capital Expenditures | -2.13K | 0 | 0 | -1.83K | -40.01M | 0 | 0 | 0 | -5.75M | -6.35M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 113.16% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5M | 0 | -4.4M |
Cash from Financing | 10.88M | 17.3M | 11.15M | 22.9M | 120.47M | 0 | 13.83M | 9.97M | 33.3M | 46.91M |
Debt Issued (Net) | 4.21M | 0 | 0 | 164.58K | -172.97K | 0 | 0 | 0 | 1M | -1M |
Equity Issued (Net) | 0 | 16.17M | 11.12M | 15.58M | 89.43M | 0 | 13.8M | 13.8M | 32.3M | 26.03M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 6.67M | 1.13M | 23.22K | 7.16M | 31.21M | 0 | 31.27K | -3.83M | 0 | 21.88M |
Net Change in Cash | 2.91M▲ 0% | 5.98M▲ 105.5% | -1.29M▼ 121.6% | 5.97M▲ 562.4% | 56.21M▲ 842.2% | -28.36M▼ 150.5% | -15.23M▲ 46.3% | -23.23M▼ 52.5% | 1M▲ 104.3% | 4.56M▲ 0% |
Free Cash Flow | -7.97M▲ 0% | -11.32M▼ 41.9% | -12.44M▼ 9.9% | -16.93M▼ 36.1% | -64.26M▼ 279.5% | -28.36M▲ 55.9% | -29.06M▼ 2.5% | -28.2M▲ 3.0% | -26.55M▲ 5.8% | -31.6M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | -563.07% |
FCF Growth % | -35.13% | -41.95% | -9.89% | -36.14% | -279.49% | 55.86% | -2.46% | 2.96% | 5.85% | -34.19% |
FCF per Share | -21.81 | -15.82 | -9.25 | -6.49 | -8.88 | -2.91 | -2.88 | -2.43 | -2.40 | -1.41 |
FCF Conversion (FCF/Net Income) | 0.77x | 0.90x | 0.80x | 0.96x | 1.05x | 0.84x | 0.89x | 0.72x | 0.71x | 0.68x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CTXR Key Ratios
Citius Pharmaceuticals, Inc. (CTXR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -53.65% | -50.33% | -59.64% | -60.46% | -27.79% | -28.48% | -33.4% | -47.29% | -49.38% | -60.07% |
Return on Invested Capital (ROIC) | -41.54% | -54.76% | -65.89% | -70.24% | -41.66% | -39.68% | -43.1% | -46.13% | -39.53% | -60.18% |
Gross Margin | - | - | - | - | - | - | - | - | - | 37.36% |
Net Margin | - | - | - | - | - | - | - | - | - | -823.34% |
Debt / Equity | 0.01x | 0.01x | 0.01x | 0.04x | 0.01x | 0.01x | 0.01x | 0.00x | 0.02x | 0.01x |
Interest Coverage | -11.74x | -790.55x | -945.43x | -1118.64x | -2125.99x | -131.52x | - | - | -143.46x | -127.90x |
FCF Conversion | 0.77x | 0.90x | 0.80x | 0.96x | 1.05x | 0.84x | 0.89x | 0.72x | 0.71x | 0.68x |
Revenue Growth | - | - | - | - | - | - | - | - | - | 3498.76% |
Related:CTXR Dividend History·CTXR Revenue History·CTXR Price History·CTXR P/E History·CTXR Financial Ratios·CTXR Institutional Holders
CTXR SEC Filings & Documents
Citius Pharmaceuticals, Inc. (CTXR) SEC filings — annual & quarterly reports (10-K, 10-Q)
CTXR Frequently Asked Questions
Citius Pharmaceuticals, Inc. (CTXR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Citius Pharmaceuticals, Inc. (CTXR) reported $5.6M in revenue for fiscal year 2025.
Citius Pharmaceuticals, Inc. (CTXR) grew revenue by 0.0% over the past year. Growth has been modest.
Citius Pharmaceuticals, Inc. (CTXR) reported a net loss of $46.2M for fiscal year 2025.
Dividend & Returns
Citius Pharmaceuticals, Inc. (CTXR) has a return on equity (ROE) of -49.4%. Negative ROE indicates the company is unprofitable.
Citius Pharmaceuticals, Inc. (CTXR) had negative free cash flow of $31.6M in fiscal year 2025, likely due to heavy capital investments.